Literature DB >> 30181938

Is it always cancer? A curious case of benign intracranial hypertension in chronic myeloid leukemia.

Purva V Sharma1, Omar Ilyas1, Yash Jobanputra1, Teresita Casanova2, Venkat Kalidindi1, Napolean Santos3.   

Abstract

28-year-old African American female with chronic myeloid leukemia (CML) presented with blurry vision for 4-5 days prior to presentation associated with right-sided headaches. Patient was on treatment for the CML but never had hematological remission. Patient saw an ophthalmologist who told her that she has bilateral optic disc swelling and advised her to get an MRI of the brain. She came to the ER due to worsening headache and blurry vision. The funduscopic examination showed significant bilateral papilledema. Laboratory evaluation revealed a leukocytosis of 240 × 103/uL with platelet count of 1,202 × 103. The white cell differential count showed 17% blasts along with myelocytes and meta-myelocytes. MRI of brain revealed non-specific CSF flair signal. Lumbar puncture (LP) showed significantly elevated opening pressures. The CSF composition was however normal. The patient felt much relief of her symptoms following the LP. The papilledema was thought to be due to benign intracranial hypertension (ICH), which was attributed to poor CSF absorption due to resistance to flow of CSF caused by the high WBC count. She received 2 cycles of leukopheresis which dropped her WBC count. She was also started on acetazolamide for the benign ICH and her symptoms improved considerably. Patients with CML can thus present with symptoms mimicking CNS involvement of the disease such as headaches and blurry vision, but that could be attributed to the poor CSF resorption given the leukocytosis rather than spread of the disease itself.

Entities:  

Keywords:  Intracranial hypertension; chronic myeloid leukemia; papilledema

Year:  2018        PMID: 30181938      PMCID: PMC6119664          DOI: 10.5582/irdr.2018.01045

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  10 in total

1.  Benign forms of intracranial hypertension; toxic and otitic hydrocephalus.

Authors:  J FOLEY
Journal:  Brain       Date:  1955       Impact factor: 13.501

2.  Ocular involvement in leukemia and allied disorders.

Authors:  R A ALLEN; B R STRAATSMA
Journal:  Arch Ophthalmol       Date:  1961-10

3.  Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.

Authors:  Hyun Jung Kim; Chul Won Jung; Kihyun Kim; Jin Seok Ahn; Won Seog Kim; Kwan Park; Young Hye Ko; Won Ki Kang; Keunchil Park
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

4.  Isolated central nervous system blast crisis in chronic myeloid leukemia.

Authors:  Senthil Rajappa; Shantveer G Uppin; D Raghunadharao; I Satish Rao; Anjna Surath
Journal:  Hematol Oncol       Date:  2004-12       Impact factor: 5.271

5.  Relationships between intracranial pressure, ventricular size, and resistance to CSF outflow.

Authors:  S E Børgesen; F Gjerris
Journal:  J Neurosurg       Date:  1987-10       Impact factor: 5.115

6.  Leukemic infiltration of the optic nerve head.

Authors:  W Ellis; H L Little
Journal:  Am J Ophthalmol       Date:  1973-05       Impact factor: 5.258

7.  A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis.

Authors:  Shahzad Shafique; Robert Bona; Andre A Kaplan
Journal:  Ther Apher Dial       Date:  2007-04       Impact factor: 1.762

8.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

9.  Benign intracranial hypertension in chronic myeloid leukemia.

Authors:  R H Guymer; J D Cairns; J O'Day
Journal:  Aust N Z J Ophthalmol       Date:  1993-08

10.  Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.

Authors:  Abdullah Altintas; Timucin Cil; Ilhan Kilinc; Muhammet Ali Kaplan; Orhan Ayyildiz
Journal:  J Neurooncol       Date:  2007-02-23       Impact factor: 4.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.